A new study led by researchers at the Icahn School of Medicine at Mount Sinai has found that adding the targeted therapy ...

UCLA’s cancer research has been deeply impactful, with millions of people receiving drugs and therapies developed in Bruin ...

The upcoming Clinical Trials in Rare Diseases conference will cover the most concerning challenges in rare disease research.

Tryptamine Therapeutics has struck an exclusive deal with world-leading psychedelic researchers Professor Robin ...

Strategic leadership appointment strengthens company’s commercial approach to drive continued growth and deliver long-term value ...

While phase 1 data suggest the novel vaccine can boost immunity and reduce relapse in pancreatic and colorectal cancer, experts remain cautious at this initial stage.

Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company focused on keeping cancer patients alive, today announced that it has entered into a definitive securities purchase agreement ...

Correa and Bergman are co-chairs of the congressional Psychedelics Advancing Therapies (PATH) Caucus. Mercer is a Marine Corps veteran and the executive director of Healing Breakthrough.

Today, the value of this approach is widely recognised even by most pharmaceutical companies, a number of which – including Sanofi, Roche and Genentech, Bayer, and Merck KgaA – have partnered with ...

Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (Upstream: QNTM) ("Quantum BioPharma" or the "Company"), a biopharmaceutical company dedicated ...

HURA READ THE FULL HURA RESEARCH REPORT Operational and Financial Results On August 15th, 2025, TuHURA Biosciences, Inc.

Reviewers winnowed an initial 27 assays to a group of nine that were evaluated using NCI sample sets, ultimately choosing ClearNote's Avantect and Guardant's Shield.